Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Peripheral T-Cell Lymphoma: early-phase trial registry
14 of 35 indexed Peripheral T-Cell Lymphoma trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #435 of 28,707 conditions by registered trial count.
35 US clinical trials · 14 currently recruiting · #435 of 28,707 conditions by registered trial count
Peripheral T-Cell Lymphoma: 35 US clinical trials tracked, 14 recruiting.
Peripheral T-Cell Lymphoma is the subject of 35 registered US clinical trials on ClinicalTrials.gov, 14 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 32 in Phase 1-2 (earlier-stage). The most active sponsor is National Cancer Institute (NCI), running 3 of these trials.
Enrollment posture brief
Registry condition peripheral-t-cell-lymphoma
OPEN 14 | RECR 40% | LATE 1 | EARLY 32 | RANK #435 | SPON 3
Volume-matched condition peers
Nearest open-share peer: Achondroplasia (40% recruiting · 10 trials)
Peripheral T-Cell Lymphoma lists 14 open slots (40% of 35 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Peripheral T-Cell Lymphoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Peripheral T-Cell Lymphoma recruits in line with its size-band peers.
14 of 35 indexed trials (40%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Peripheral T-Cell Lymphoma trials is spread across many organizations.
National Cancer Institute (NCI) accounts for 3 of 35 trials (8.6%). 30 distinct sponsors appear on at least one study for this condition label.
-
Most Peripheral T-Cell Lymphoma trials plan to enrol fewer than 100 people.
Median target enrolment is 44 among the 35 trials that report a genuine target (sentinel values excluded). 25 of those (71.4%) plan for fewer than 100 participants.
-
Peripheral T-Cell Lymphoma research is mostly interventional.
34 interventional and 1 observational studies make up this index (97.1% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
35 total, page 1 of 1
Prospective Observational International Registry of Patients With Newly Diagnosed Peripheral T Cell Lymphoma.
Associazione Angela Serra per la ricerca sul cancro
NCT03964480
To Evaluate Efficacy of Belinostat or Pralatrexate in Combination Against CHOP Alone in PTCL
Acrotech Biopharma
NCT06072131
Evaluate the Safety and Clinical Activity of HH2853
Haihe Biopharma Co.
NCT04390737
Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies
CellCentric
NCT04068597
Constitutive IL7R (C7R) Modified Banked Allogeneic CD30.CAR EBVSTS for CD30-Positive Lymphomas
Baylor College of Medicine
NCT06176690
A Phase I Trial Anti-CC Chemokine Receptor 4 Chimeric Antigen Receptor T Cells (CCR4 CAR T Cells) for CCR4 Expressing T-cell Malignancies Including Peripheral T-cell Non-Hodgkin Lymphoma (PTCL) and Cutaneous T-cell Non-Hodgkin Lymphoma (CTCL)
National Cancer Institute (NCI)
NCT07055477
Amping up With PemJAK
Seda S. Tolu
NCT07283822
Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma
SciTech Development
NCT04234048
Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant T-Cell Lymphoma
Jonathan Brammer
NCT07356245
Chemoimmunotherapy and Allogeneic Stem Cell Transplant for NK T-cell Leukemia/Lymphoma
New York Medical College
NCT03719105
A Phase II, Single-center, Single-arm Study Evaluating the Safety and Efficacy of Golidocitinib in the Management of Newly Diagnosed Peripheral T Cell Lymphoma Patients (GOLDEN Study) and Correlative Study
M.D. Anderson Cancer Center
NCT06630091
Intravenous Vesicular Stomatitis Virus in Patients With Peripheral T-cell Lymphoma
Mayo Clinic
NCT06508463
CD30 CAR for Relapsed/Refractory CD30+ T Cell Lymphoma
UNC Lineberger Comprehensive Cancer Center
NCT04083495
A Pilot of a Microdevice For In Situ Candidate Drug Screening in Cutaneous Lesions of T-Cell Lymphoma
Dana-Farber Cancer Institute
NCT04045470
Romidepsin and Lenalidomide in Treating Patients With Previously Untreated Peripheral T-Cell Lymphoma
Northwestern University
NCT02232516
Phase 1 Study of Autologous CD30.CAR-T in Relapsed or Refractory CD30 Positive Non-Hodgkin Lymphoma
Tessa Therapeutics
NCT04526834
A Study to Learn About the Study Medicine Called PF-08046032 in People With Advanced Cancers
Pfizer
NCT06870487
Dose-Escalation and Dose-Expansion Study to Evaluate the Safety and Tolerability of Anti-CD7 Allogeneic CAR T-Cells (WU-CART-007) in Patients With CD7+ Hematologic Malignancies
Washington University School of Medicine
NCT05377827
A Study of Duvelisib in Participants With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)
SecuraBio
NCT03372057
Depsipeptide to Treat Patients With Cutaneous T-Cell Lymphoma and Peripheral T-Cell Lymphoma
National Cancer Institute (NCI)
NCT00007345
A Study of Brentuximab Vedotin With Hodgkin Lymphoma (HL) and CD30-expressing Peripheral T-cell Lymphoma (PTCL)
Seagen
NCT01716806
Belinostat in Relapsed or Refractory Peripheral T-Cell Lymphoma
Spectrum Pharmaceuticals
NCT00865969
Study of Pralatrexate With Vitamin B12 and Folic Acid in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma
Acrotech Biopharma
NCT00364923
Phase II Study to Assess AFM13 in Patients With R/R CD30-positive T-cell Lymphoma or Transformed Mycosis Fungoides
Affimed
NCT04101331
Pembrolizumab After ASCT for Hodgkin Lymphoma, DLBCL and T-NHL
Dana-Farber Cancer Institute
NCT02362997
A Study of Brentuximab Vedotin and CHP in Frontline Treatment of PTCL With Less Than 10% CD30 Expression
Seagen, a wholly owned subsidiary of Pfizer
NCT04569032
Oral Clofarabine for Relapsed/Refractory Non-Hodgkin Lymphoma
Massachusetts General Hospital
NCT00644189
Panobinostat in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
Mayo Clinic
NCT01261247
BR101801 in Adult Patients With Advanced Hematologic Malignancies(Phase I)
Boryung Pharmaceutical Co.
NCT04018248
Methoxyamine and Fludarabine Phosphate in Treating Patients With Relapsed or Refractory Hematologic Malignancies
Case Comprehensive Cancer Center
NCT01658319
Carfilzomib in Treating Patients With Relapsed or Refractory T-Cell Lymphoma
University of Nebraska
NCT01336920
Sorafenib Tosylate in Treating Patients With Recurrent Aggressive Non-Hodgkin's Lymphoma
National Cancer Institute (NCI)
NCT00131937
Bortezomib and Azacitidine in Treating Patients With Relapsed or Refractory T-Cell Lymphoma
Pierluigi Porcu
NCT01129180
Letermovir for the Prevention of Cytomegalovirus Reactivation in Patients With Hematological Malignancies Treated With Alemtuzumab
Ohio State University Comprehensive Cancer Center
NCT04312841
Nivolumab and the Antagonistic CSF-1R Monoclonal Antibody Cabiralizumab (BMS-986227) in Patients With Relapsed/Refractory Peripheral T Cell Lymphoma
University of Michigan Rogel Cancer Center
NCT03927105
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 15 |
| Phase 2 | 17 |
| Phase 3 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Peripheral T-Cell Lymphoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Peripheral T-Cell Lymphoma trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Peripheral T-Cell Lymphoma page
35 registered trials, 14 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 14 Peripheral T-Cell Lymphoma trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- National Cancer Institute (NCI) sponsors the most Peripheral T-Cell Lymphoma trials on record, review their full trial history before evaluating a specific study. See National Cancer Institute (NCI)'s trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Peripheral T-Cell Lymphoma condition card totals 35 registered trials; most-linked intervention laboratory biomarker analysis; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.